How the New EU Product Liability Directive Impacts Irish Businesses

The landscape of consumer protection and corporate accountability is poised for a seismic shift across the European Union, and the Republic of Ireland is no exception. With the advent of the new Product Liability Directive EU 2024/2853, lawmakers in Brussels have initiated the most comprehensive overhaul of product safety legislation in nearly four decades. Mandated to be transposed into Irish national law by the 9th of December 2026, this robust framework aims to modernise the legal structures governing defective goods, ensuring they remain fit for purpose in an increasingly digitalised and interconnected global economy. For Irish businesses, ranging from indigenous manufacturing enterprises to the sprawling multinational technology hubs situated in Dublin's Silicon Docks, the implications of this new directive are profound. The upcoming legislative changes will unequivocally strengthen the legal protections and certainty afforded to claimants, simultaneously imposing stringent new compliance and liability burdens on manufacturers, importers, and distributors operating within the State.

Historically, product liability in Ireland has been governed by the Liability for Defective Products Act 1991, which implemented the original 1985 European directive. While this legislation served as a cornerstone for consumer protection, establishing the principle of strict liability for defective physical goods, it has grown increasingly antiquated in the face of modern technological advancements. The proliferation of smart devices, artificial intelligence, and complex global supply chains exposed significant gaps in the existing legal framework. The newly minted directive seeks to bridge these chasms, recalibrating the balance of power between consumers who suffer harm and the commercial entities responsible for placing products onto the market. As the transposition deadline steadily approaches, legal practitioners and corporate governance experts across Ireland are urging businesses to proactively assess their exposure and implement necessary operational adjustments long before the new statutory regime takes effect.

The Reclassification of Software as a Product

Perhaps the most revolutionary aspect of the new directive is its explicit expansion of the definition of a "product" to include software. Under the traditional Irish legal framework, software was frequently categorised as a service rather than a tangible good, thereby existing in a somewhat nebulous grey area concerning strict product liability. The new directive eradicates this ambiguity, expressly stipulating that software, whether integrated into a physical device or supplied as a standalone product, falls squarely within the ambit of product liability law. This paradigm shift means that software developers, publishers, and distributors may now be exposed to substantial liability claims in the event that defective code causes physical harm, psychological damage, or significant data corruption.

For the Irish economy, which is heavily reliant on its thriving technology and software-as-a-service sectors, the inclusion of software as a product carries monumental implications. Ireland serves as the European headquarters for numerous global technology titans, alongside a vibrant ecosystem of indigenous digital startups. Under the impending legal regime, an error in a diagnostic medical application, a glitch in an autonomous vehicle's navigation system, or a vulnerability in a smart home security network could trigger severe legal repercussions. Irish technology firms must now navigate a landscape where they are held to the same strict liability standards as traditional manufacturers of physical goods. Consequently, rigorous software testing, comprehensive quality assurance protocols, and meticulous documentation will transition from being industry best practices to absolute legal necessities.

Shifting the Burden of Proof in Favour of Claimants

Another critical transformation introduced by the directive is the recalibration of the burden of proof, which has historically been a significant hurdle for claimants seeking redress in the Irish courts. Previously, an injured party was required to conclusively prove the defect in the product, the damage suffered, and the direct causal link between the two. In highly complex cases involving sophisticated pharmaceuticals, intricate mechanical failures, or opaque algorithmic software, establishing this causal nexus on the balance of probabilities often proved to be an insurmountable, prohibitively expensive challenge for the average consumer.

The new directive dramatically alters this dynamic by introducing a more favourable evidentiary regime for claimants. Under the updated rules, national courts, including the Irish High Court and Circuit Court, will be empowered to presume that a product is defective if the claimant can demonstrate a plausible link between the product's performance and the damage sustained. Furthermore, if a defendant fails to disclose necessary technical information requested by the claimant, the courts may automatically presume defectiveness. This alleviation of the burden of proof is expected to streamline the litigation process and significantly lower the barrier to entry for injured parties initiating claims. It is also highly likely to influence the dynamics of claims processed through the Injuries Resolution Board, as the threat of successful litigation becomes a more potent leverage point for claimants during early-stage settlement negotiations.

Extended Limitation Periods for Latent Harm

The temporal scope of liability is also undergoing a substantial expansion, forcing Irish businesses to re-evaluate their long-term risk management strategies. Under the existing framework, the right to initiate a product liability claim was subject to a strict long-stop limitation period of ten years from the date the product was placed on the market. Once this decade-long window closed, manufacturers were generally shielded from strict liability claims, regardless of when the defect was discovered or when the injury occurred. The new directive extends this standard long-stop limitation period from ten to fifteen years in most standard cases, reflecting the extended lifespan and durability of modern consumer goods.

More critically, the directive introduces a groundbreaking extension of up to twenty-five years in scenarios where the harm caused by a defective product manifests slowly over an extended period. This provision is particularly relevant for latent injuries, such as those resulting from long-term exposure to toxic chemicals, gradual environmental contamination, or the delayed failure of surgically implanted medical devices. For Irish enterprises, particularly those operating in the pharmaceutical, life sciences, and heavy manufacturing sectors, this means that liability exposure will extend over a significantly longer horizon. Defending claims a quarter of a century after a product was manufactured presents formidable logistical challenges, including the retention of manufacturing records, the availability of key personnel for witness testimony, and the preservation of technical design specifications.

Strategic Imperatives for Irish Enterprises

As the December 2026 transposition deadline approaches, complacency is not a viable strategy for Irish product manufacturers, importers, and distributors. The confluence of expanded product definitions, relaxed evidentiary burdens for claimants, and extended limitation periods creates a highly heightened risk environment. Businesses must immediately begin conducting comprehensive audits of their entire operational lifecycle to identify vulnerabilities under the new legislative framework. Supply chain due diligence will become paramount, as entities that import goods into the European Union or modify products substantially may find themselves bearing the full brunt of manufacturer liability.

Furthermore, a thorough review of commercial contracts and indemnification clauses is urgently required. Irish companies must ensure that liability is appropriately apportioned among supply chain partners, software developers, and component manufacturers. Equally important is an immediate consultation with insurance brokers and underwriters. Traditional product liability and professional indemnity policies may not provide adequate coverage for the extended limitation periods or the novel inclusion of software-related damages. By proactively updating product safety procedures, enhancing post-market surveillance, and securing robust insurance coverage, Irish businesses can successfully navigate this transformative era in European product liability law and safeguard their commercial viability for decades to come.